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A B S T R A C T

Summary Coronavirus disease 2019 (COVID-19) is rapidly evolving with millions of cases and death reported globally.
The ﬁrst-ever case of COVID-19 in Bhutan was conﬁrmed on 5 March 2020 in a 76-year-old American tourist. The national regulatory authorities have implemented varying degrees of regulatory ﬂexibilities to prevent unnecessary
death by ensuring timely access to medical products and technologies during the pandemic. The Drug Regulatory Authority of Bhutan, as a national medicines regulatory agency responsible for ensuring the quality of medical products
has implemented several regulatory mechanisms to ensure access to medical products including COVID-19 vaccines
during the pandemic. In this commentary, we discuss the regulatory ﬂexibilities that ensured access to medical products and COVID-19 vaccines during the pandemic.

1. Introduction
Coronavirus disease 2019 (COVID-19) is rapidly evolving and as of 8
May 2022, over 521 million conﬁrmed cases and more than six million
deaths have been reported globally.1 The ﬁrst-ever case of COVID-19 in
Bhutan was conﬁrmed on 5 March 2020 in a 76-year-old American tourist.2
Since then, Bhutan reported 59,552 conﬁrmed cases and 21 deaths so far.3
COVID-19 pandemic has induced severe disruptions to the healthcare
system4 including the national medicines regulatory systems. The national
regulatory authorities have implemented varying degrees of regulatory
ﬂexibilities to prevent unnecessary death by ensuring timely access to medical products and technologies during the pandemic.5
Since the beginning of the COVID-19 pandemic in Bhutan, His Majesty,
the King commanded the government to do everything possible to keep
every Bhutanese safe from COVID-19.6 In response, the government has developed and implemented several COVID-19 support programs for people
affected by the pandemic. The Drug Regulatory Authority of Bhutan
(DRA) as a national responsible agency for ensuring the quality of medical
products,7 has implemented several regulatory mechanisms to provide access to medical products including the COVID-19 vaccines during the pandemic.
In Bhutan, basic healthcare services are provided free of cost by the
State. However, Bhutan is largely dependent on imported medical products.
The Medicines Act of the Kingdom of Bhutan deﬁnes vaccines and biological as medical products,8 and all medical products imported and distributed
for use in the country must be registered with the DRA.9 This means every

single medical product needs to be technically reviewed and approved and
this process usually takes a minimum of two months. However, providing
access to and facilitating prompt delivery of medical products, especially
COVID-19 vaccines during the pandemic is critical. In this commentary,
we discuss the key regulatory mechanisms employed by the DRA to provide
access to medical products with a focus on COVID-19 vaccines during the
pandemic.
2. Regulatory ﬂexibilities during the pandemic
Critical shortages of oxygen were reported in many countries including neighbouring India 10 and this disrupted oxygen supplies to
Bhutan. Responding to the increased demand for oxygen supplies, the
DRA expedited the licensing of new oxygen manufacturing facilities,
and the key personnel working in these facilities were exempted from
the competency assessment by the DRA. An interim guideline 11
adopted for the regulation of surgical face masks and surgical respirators allowed community pharmacies to import and sell surgical face
masks and surgical respirators. Imported face masks were approved
based on a documentary review.
Bhutan experienced four national COVID-19 lockdowns ranging from
21 to 42 days.12 The DRA appointed service delivery focal persons who
worked during the lockdowns to deliver essential regulatory services such
as import authorizations, vaccine lot release, and product registration. A
team of ofﬁcials travelled across 17 districts to monitor adverse events following immunizations in 220 and 214 vaccination sites during the ﬁrst and
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second vaccination campaigns, respectively. Community pharmacies were
permitted to operate in respective zones during the lockdowns to facilitate
home delivery of basic essential medicines in coordination with the Ministry of Health. The product samples required to be submitted for the registration of medical products were exempted to ease the regulatory burden.

No funding sources.

Availability of data and materials
3. Emergency use authorization for COVID-19 vaccines

Not applicable.

An emergency use authorization (EUA) is a regulatory mechanism
adopted by national regulatory authorities to approve the use of unapproved medical products (or unapproved uses of approved medical products) to manage declared public health emergencies for which there are
no adequate, approved, and available alternatives.13 In Bhutan, EUA for
COVID-19 vaccines and COVID-19 antigen self-test kits were granted by
the DRA. Acknowledging the unprecedented speed at which the COVID19 vaccines were being developed and the complexity involved in performing a complete, independent assessment of the safety, efﬁcacy and quality
of such vaccines, a recognition and reliance mechanism was adopted to leverage the assessment conducted by stringent national regulatory authorities or Pharmaceutical Inspection Committee/Schemes member countries.
The guideline for EUA was formulated to ensure rapid access to COVID19 vaccines.
Approval processes for EUA were signiﬁcantly expedited by reducing
turnaround time from 60 days to 7 days by a dedicated team of regulatory
ofﬁcials who reviewed the applications for EUA vis-à-vis the national regulatory requirements. The ﬁrst EUA for the COVID-19 vaccine was granted
on 17 March 2021. Since then, EUA was granted for all six COVID-19 vaccines and 4 antigen self-test kits used in the country. Similarly, lot release
certiﬁcates for COVID-19 vaccines were issued on the date of arrival of
the consignment to complement the government's effort for the rapid delivery of COVID-19 vaccines.
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4. Conclusion
The Medicines Act8 does not provide an exemption for vaccine lot release during public health emergencies. This could potentially compromise
the vaccine cold chain in resource-limited settings where vaccines are required to be quickly distributed to health centres owing to the scarcity of
cold chain facilities. Therefore, future amendments of the legislation may
include exemption of vaccines lot release during public health emergencies
like the COVID-19 pandemic. Reliance mechanisms can be cost-effective for
a resource-constrained country like Bhutan but excessive adoption of reliance and recognition mechanisms without adequate systems in place to
oversee the products could create a potential regulatory loophole through
which substandard medical products may enter the supply chain. There is
a need for training of regulatory ofﬁcials on good reliance practices to manage risk ensuing from reliance mechanisms.
Going forward in the post-pandemic era, regularizing EUA to routine
marketing approvals needs to be carefully monitored and implemented.
Continuing with regulatory processes adopted during the pandemic could
disrupt the whole regulatory system, creating an avenue for substandard
products to enter the market. There must be a clear timeline for how long
the regulatory exemptions introduced during the pandemic will continue.
The reactive regulatory approach adopted and implemented during the
pandemic may have to continue or be replaced post-pandemic. Hence,
proper evaluation and risk-beneﬁt rationality must guide such decision
makings.
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